ISSN: 2161-1149 (Printed)
Jing Li*, Xiang Dong Jia, Junling Ge, Guoen Yao
With the global COVID-19 pandemic, a substantial number of patients have developed neurological lesions, including CLOCCs (Cytotoxic Lesion of the Corpus Callosum). CLOCCs is a rare, self-limited central nervous system disease that is characterized by a decrease in the Apparent Diffusion Coefficient (ADC) of the corpus callosum. It is currently considered to be caused by cytotoxic edema [1]. There are many causes of CLOCCs, among which infection and trauma are the most common. The neurological symptoms of CLOCCs, including changes in behavior and consciousness, neck stiffness, delirium, irritability, hallucinations, dizziness, transient disturbance of consciousness, epilepsy, cognitive impairment, dyskinesia, dysarthria, slurred speech, ataxia, visual impairment, and acute urinary retention, are known to be common neurological symptoms [2]. However, there are still many aspects of diagnosing, treating, and understanding the pathogenesis of these patients that require further in-depth study. This article aims to provide fresh insights for future clinical diagnosis and research into the novel coronavirus's impact on the nervous system by examining and dissecting the diagnosis and treatment journey of a 40-year-old female patient who holds a doctorate in the arts and is afflicted with COVID-19-related CLOCCs.